Beta-lapachone Solubility via Bisulfite Conversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The low solubility of many quinone compounds, including β-lapachone, in pharmaceutically acceptable solvents poses a challenge for their effective pharmaceutical formulations, leading to drawbacks in pharmacokinetic profiles and bioavailability.
Innovation Solution
The development of a pharmaceutical composition comprising β-lapachone in the form of crystalline particles with a bisulfite agent, such as sodium metabisulfite, to enhance solubility and bioavailability, where the bisulfite agent converts β-lapachone into a more soluble hydroxy sulfonate form, which can revert back to β-lapachone under certain conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If quinone compounds like β-lapachone are used as anti-cancer drugs, then therapeutic efficacy is improved, but solubility in pharmaceutically acceptable solvents deteriorates
Solution Approach 1:
The patent introduces a bisulfite agent as an intermediary substance that forms a soluble complex with β-lapachone. This intermediary complex enables the quinone compound to be dissolved in aqueous pharmaceutical formulations, resolving the solubility issue while maintaining therapeutic activity. The bisulfite agent acts as a mediator that bridges the hydrophobic quinone and the hydrophilic pharmaceutical formulation.
Solution Approach 2:
The patent changes the chemical state of β-lapachone by converting it to a hydroxy sulfonate derivative through reaction with bisulfite agents. This parameter change in chemical structure transforms the compound from an insoluble quinone form to a soluble sulfonate form, enabling effective pharmaceutical formulation while preserving biological activity.
2Reliability
If quinone compounds are used as anti-cancer drugs, then therapeutic efficacy is improved, but bioavailability deteriorates
Solution Approach 1:
The bisulfite agent serves as a bioavailability enhancer that facilitates the absorption and distribution of β-lapachone in the body. By forming a soluble complex, the intermediary agent ensures the compound reaches target cancer cells effectively, improving bioavailability without compromising therapeutic efficacy.
Solution Approach 2:
The conversion of β-lapachone to its hydroxy sulfonate form changes key pharmacokinetic parameters, including solubility, absorption rate, and plasma half-life. This parameter transformation enables better bioavailability by allowing the compound to be properly absorbed and circulated in the body.
3Ease of manufacture
If traditional formulations of quinone compounds are used, then manufacturing simplicity is maintained, but pharmacokinetic profiles deteriorate
Solution Approach 1:
The bisulfite agent acts as a formulation additive that modifies the pharmacokinetic profile of β-lapachone. By incorporating this intermediary substance into the formulation, the patent extends plasma half-life and improves pharmacokinetic parameters while maintaining relatively simple manufacturing processes.
Solution Approach 2:
The formation of the hydroxy sulfonate derivative changes critical pharmacokinetic parameters including plasma half-life, clearance rate, and distribution volume. This parameter change results in improved duration of action and better overall pharmacokinetic profile.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly improves the solubility, stability, and bioavailability of β-lapachone, leading to enhanced therapeutic efficacy and improved plasma half-life, addressing the limitations of traditional formulations.
Implementation Method 1
the bisulfite agent converts β-lapachone into a more soluble hydroxy sulfonate form
Implementation Method 2
which can revert back to β-lapachone under certain conditions
Data Source
Figure 1A~1B
Figure 1C
Figure 2A~2B
AI summary
The present invention provides sodium 6-hydroxy-2,2-dimethyl-5-oxo-3,4,5,6-tetrahydro-2H- benzo(h)chromene-6-sulfonate, and its synthesis and uses in the treatment of cancer.